| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.3 | 4e-09 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.26 | 2e-08 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.29 | 5e-08 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.39 | 1e-07 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-07 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.39 | 1e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-06 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.21 | 5e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.24 | 8e-06 |